Overarching principles for vaccination in adult patients with AIIRD
| Overarching principles | Level of Agreement (%) | |
| 1. | The vaccination status and indications for further vaccination in patients with AIIRD should be assessed yearly by the rheumatology team. | 100% |
| 2. | The individualised vaccination programme should be explained to the patient by the rheumatology team, providing a basis for shared decision-making, and be jointly implemented by the primary care physician, the rheumatology team and the patient. | 94% |
| 3. | Vaccination in patients with AIIRD should preferably be administered during quiescent disease. | 94% |
| 4. | Vaccines should preferably be administered prior to planned immunosuppression, in particular B cell depleting therapy. | 100% |
| 5. | Non-live vaccines can be administered to patients with AIIRD also while treated with systemic glucocorticoids and DMARDs. | 100% |
| 6. | Live-attenuated vaccines may be considered with caution in patients with AIIRD. | 53% |
AIIRD, autoimmune inflammatory rheumatic diseases; DMARDs, disease-modifying antirheumatic drugs.